Ding Li-Na, Ding Wen-Yu, Ning Jie, Wang Yao, Yan Yan, Wang Zhi-Bin
Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Shandong Institute of Endocrine and Metabolic Diseases, Jinan, China.
Front Pharmacol. 2021 Dec 10;12:770861. doi: 10.3389/fphar.2021.770861. eCollection 2021.
Several studies have revealed the effect of probiotic supplementation in patients with type 2 diabetes (T2DM) on the amelioration of low-grade inflammation, which plays an important role in the pathogenesis of T2DM. However, the effects of the clinical application of probiotics on inflammation in individuals with T2DM remain inconsistent. This study aims to investigate the comprehensive effects of probiotics on inflammatory markers in adults with T2DM. PubMed, Embase, Cochrane Library, and the Web of Science were searched to identify randomized controlled trials (RCTs) exploring the effect of probiotic supplementation on inflammatory markers in individuals with T2DM through March 11, 2021. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies. We used a random-effects model to calculate the standardized mean difference (SMD) between the probiotic supplementation and control groups. Seventeen eligible studies were selected with a total of 836 participants, including 423 participants in probiotic supplementation groups and 413 participants in control groups. Our study demonstrated that compared with the control condition, probiotic intake produced a beneficial effect in reducing the levels of plasma inflammation markers, including tumour necrosis factor-α (TNF-α) (SMD [95% CI]; -0.37 [-0.56, -0.19], < 0.0001) and C-reactive protein (CRP) (SMD [95% CI]; -0.21 [-0.42, -0.01], = 0.040), while it had no effect on the plasma interleukin-6 (IL-6) level (SMD [95% CI]; -0.07 [-0.27, 0.13], = 0.520). In addition, our results support the notion that probiotic supplementation improves glycaemic control, as evidenced by a significant reduction in fasting blood glucose (FPG), HbA1c and HOMA-IR (SMD [95% CI]: -0.24 [-0.42, -0.05], = 0.010; -0.19 [-0.37, -0.00], = 0.040; -0.36 [-0.62, -0.10], = 0.006, respectively). Our study revealed some beneficial effects of probiotic supplementation on improving inflammatory markers and glucose homeostasis in individuals with T2DM. Probiotics might be a potential adjuvant therapeutic approach for T2DM.
多项研究揭示了补充益生菌对2型糖尿病（T2DM）患者减轻低度炎症的作用，低度炎症在T2DM发病机制中起重要作用。然而，益生菌临床应用对T2DM个体炎症的影响仍不一致。本研究旨在探讨益生菌对成年T2DM患者炎症标志物的综合影响。检索了PubMed、Embase、Cochrane图书馆和科学网，以识别截至2021年3月11日探索补充益生菌对T2DM个体炎症标志物影响的随机对照试验（RCT）。两名 reviewers 独立筛选文献、提取数据并评估纳入研究的偏倚风险。我们使用随机效应模型计算补充益生菌组与对照组之间的标准化平均差（SMD）。共选择了17项符合条件的研究，包括836名参与者，其中补充益生菌组423名参与者，对照组413名参与者。我们的研究表明，与对照情况相比，摄入益生菌对降低血浆炎症标志物水平产生了有益影响，包括肿瘤坏死因子-α（TNF-α）（SMD [95% CI]；-0.37 [-0.56, -0.19]，<0.0001）和C反应蛋白（CRP）（SMD [95% CI]；-0.21 [-0.42, -0.01]，=0.040），而对血浆白细胞介素-6（IL-6）水平无影响（SMD [95% CI]；-0.07 [-0.27, 0.13]，=0.520）。此外，我们的结果支持补充益生菌可改善血糖控制的观点，空腹血糖（FPG）、糖化血红蛋白（HbA1c）和胰岛素抵抗指数（HOMA-IR）显著降低证明了这一点（SMD [95% CI]：-0.24 [-0.42, -0.05]，=0.010；-0.19 [-0.37, -0.00]，=0.040；-0.36 [-0.62, -0.10]，=0.006，分别）。我们的研究揭示了补充益生菌对改善T2DM个体炎症标志物和葡萄糖稳态的一些有益作用。益生菌可能是T2DM的一种潜在辅助治疗方法。
